Syngene International Management

Management Kriterienprüfungen 2/4

Syngene International's CEO ist Jonathan Hunt, ernannt in Jan 2016, hat eine Amtszeit von 8.33 Jahren. Die jährliche Gesamtvergütung beträgt ₹84.75M, bestehend aus 100% Gehalt und 0% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.087% der Aktien des Unternehmens, im Wert von ₹234.73M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.3 Jahre bzw. 6.8 Jahre.

Wichtige Informationen

Jonathan Hunt

Geschäftsführender

₹285.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	50.0%
Amtszeit als Geschäftsführer	8.7yrs
Eigentum des Geschäftsführers	0.06%
Durchschnittliche Amtszeit des Managements	7.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.1yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jonathan Hunt im Vergleich zu den Einnahmen von Syngene International verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	₹5b
Mar 31 2024	₹285m	₹143m	₹5b
Dec 31 2023	n/a	n/a	₹5b
Sep 30 2023	n/a	n/a	₹5b
Jun 30 2023	n/a	n/a	₹5b
Mar 31 2023	₹85m	₹85m	₹5b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹4b
Jun 30 2022	n/a	n/a	₹4b
Mar 31 2022	₹76m	₹76m	₹4b
Dec 31 2021	n/a	n/a	₹4b
Sep 30 2021	n/a	n/a	₹4b
Jun 30 2021	n/a	n/a	₹4b
Mar 31 2021	₹65m	₹65m	₹4b
Dec 31 2020	n/a	n/a	₹4b
Sep 30 2020	n/a	n/a	₹4b
Jun 30 2020	n/a	n/a	₹4b
Mar 31 2020	₹66m	₹66m	₹4b
Dec 31 2019	n/a	n/a	₹4b
Sep 30 2019	n/a	n/a	₹4b
Jun 30 2019	n/a	n/a	₹3b
Mar 31 2019	₹90m	₹47m	₹3b
Dec 31 2018	n/a	n/a	₹3b
Sep 30 2018	n/a	n/a	₹3b
Jun 30 2018	n/a	n/a	₹3b
Mar 31 2018	₹94m	₹47m	₹3b

Vergütung im Vergleich zum Markt: JonathanDie Gesamtvergütung ($USD1.02M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD509.33K).

Entschädigung vs. Einkommen: JonathanDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Jonathan Hunt (55 yo)

8.7yrs

Amtszeit

₹285,330,000

Vergütung

Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jonathan Hunt	MD, CEO & Executive Director	8.7yrs	₹285.33m	0.062% ₹ 218.1m
Sibaji Biswas	CFO & Executive Director	4.8yrs	₹34.14m	0.017% ₹ 59.9m
Krishnan G	Head of Investor Relations	no data	keine Daten	0.0016% ₹ 5.5m
Priyadarshini Mahapatra	Head of Legal	5.2yrs	₹4.72m	0.0024% ₹ 8.4m
Sandeep Nair	Head of Corporate Communications	no data	keine Daten	keine Daten
Andrew Webster	Chief Human Resources Officer	1.8yrs	keine Daten	keine Daten
Dhananjay Patankar	Head of Pharmaceutical & Biopharmaceutical Development	no data	₹10.80m	keine Daten
Purushottam Singnurkar	Head of Formulations Development	no data	₹5.50m	0.025% ₹ 88.0m
Ajit Manocha	Head of IT	8.6yrs	keine Daten	0.00038% ₹ 1.3m
Jayashree Aiyar	Head of Discovery Biology	8.7yrs	keine Daten	0% ₹ 0
Chetan Tamhankar	Head of Clinical Development & Stability Studies	8.7yrs	keine Daten	0.0060% ₹ 21.1m
Rajendra Patil	Head of EHSS	6.7yrs	keine Daten	0.0093% ₹ 33.0m

7.6yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: Das Managementteam von 539268 ist erfahren und erfahren (durchschnittliche Amtszeit: 7.3 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jonathan Hunt	MD, CEO & Executive Director	7.3yrs	₹285.33m	0.062% ₹ 218.1m
Sibaji Biswas	CFO & Executive Director	less than a year	₹34.14m	0.017% ₹ 59.9m
Catherine Rosenberg	Non-Executive Director	24.1yrs	₹8.28m	0.0022% ₹ 7.7m
Kiran Mazumdar-Shaw	Non-Executive Chairperson	no data	₹9.43m	0.0055% ₹ 19.3m
Vinita Bali	Lead Independent Director	7.2yrs	₹8.62m	keine Daten
Vijay Kuchroo	Independent Director	7.5yrs	₹7.46m	0.012% ₹ 44.0m
Nilanjan Roy	Additional Independent Director	less than a year	keine Daten	keine Daten
Kush Parmar	Independent Non Executive Director	3.3yrs	₹6.47m	keine Daten
Paul Blackburn	Non-Executive Independent Director	10.1yrs	₹9.12m	0.012% ₹ 44.0m
Manja Boerman	Independent Director	less than a year	keine Daten	keine Daten
Sharmila Karve	Additional Independent Director	5.1yrs	₹8.46m	keine Daten

6.1yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: 539268Die Vorstandsmitglieder gelten als erfahren (6.8 Jahre durchschnittliche Amtszeit).

Syngene International Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Insider recently sold ₹6.0m worth of stock

MD, CEO & Executive Director recently sold ₹115m worth of stock

Head of Formulations Development recently sold ₹9.6m worth of stock

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹4.9m worth of stock

Syngene International Limited, Annual General Meeting, Jul 24, 2024

Recent updates

Insider recently sold ₹6.0m worth of stock

MD, CEO & Executive Director recently sold ₹115m worth of stock

Head of Formulations Development recently sold ₹9.6m worth of stock

Syngene International Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited Approves for the Financial Year Ended March 31, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Proposes Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited to Report Q1, 2025 Results on Jul 24, 2024

New minor risk - Insider selling

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹4.9m worth of stock

Dividend of ₹1.25 announced

Syngene International Limited, Annual General Meeting, Jul 24, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Recommends Final Dividend for the Financial Year 2024

Syngene International Limited to Report Q4, 2024 Results on Apr 24, 2024

Head of IT recently sold ₹1.5m worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024

Insider recently sold ₹9.9m worth of stock

Syngene International Limited to Report Q3, 2024 Results on Jan 25, 2024

Head of Investor Relations recently sold ₹1.7m worth of stock

Head of Investor Relations recently sold ₹1.8m worth of stock

Insider recently sold ₹7.1m worth of stock

Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024

Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director

Second quarter 2024 earnings released: EPS: ₹2.90 (vs ₹2.55 in 2Q 2023)

Syngene International Limited Announces Retirement of Joydeep Kant as Sr. Vice President - Development Services, Effective October 31, 2023

Syngene International Limited to Report Q2, 2024 Results on Oct 17, 2023

Chief Financial Officer recently sold ₹57m worth of stock

Insider recently sold ₹2.4m worth of stock

Price target increased by 8.9% to ₹808

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of ₹1.25 per share at 0.1% yield

Insider recently sold ₹2.3m worth of stock

MD, CEO & Executive Director recently sold ₹166m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹2.1m worth of stock

Insider recently sold ₹4.6m worth of stock

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.9m worth of stock

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Third quarter 2023 earnings released: EPS: ₹2.74 (vs ₹2.57 in 3Q 2022)

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.4m worth of stock

Insider recently sold ₹1.0m worth of stock

Insider recently sold ₹7.8m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹4.3m worth of stock

Syngene International Limited Provides Earnings Guidance for the Year 2022

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹1.1m worth of stock

MD, CEO & Executive Director recently sold ₹20m worth of stock

Chief Human Resources Officer recently sold ₹13m worth of stock

Insider recently sold ₹4.0m worth of stock

Syngene International Limited Approves the Additional Special Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited, Annual General Meeting, Jul 20, 2022

Upcoming dividend of ₹1.00 per share

Syngene International Limited Recommends Special Additional Dividend for the Financial Year Ended March 31, 2022

Insider recently sold ₹1.7m worth of stock

Syngene International Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited to Report Q4, 2022 Results on Apr 27, 2022

Syngene International Limited Appoints Carl Decicco as Additional Director Non-Executive Non-Independent of the Company

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹2.7m worth of stock

Insider recently sold ₹6.3m worth of stock